ARCHIVES

Final Results from CLEOPATRA Phase III Trial Show Perjeta Increased OS 15.7 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

NIH Clinical Center Offers Sabbatical In Clinical Research Management

October 1, 2010

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

July 30, 1999

Solomon Garb’s Questions/Answers

January 9, 1981

Also in this 12-page issue: Senate report endorses NCI’s 2015 goal.

July 22, 2005

HCFA Firm Against Reimbursement For Patients In Clinical Trials, Lasagna Committee Hears

March 24, 1989

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009